The Lancet Global Health
-
1
[Editorial] Children with arthritis: orphans of the NCD agenda?
-
2
[Viewpoint] Beyond monitoring misery during conflict: the political economy of global health reform
-
3
[Articles] Hypoxaemia and mortality in children with lower respiratory infection in low-income and middle-income countries: systematic review and meta-analysis
-
4
[Comment] Economic case for universal hepatitis B birth dose vaccination in South Africa
-
5
[Articles] Cost-effectiveness of the hepatitis B birth-dose vaccine in South Africa: a mathematical modelling analysis
-
6
[Correspondence] Beyond geography: conflict, displacement, and structural vulnerability in noma distribution in Nigeria
-
7
[Correspondence] Beyond geography: conflict, displacement, and structural vulnerability in noma distribution in Nigeria
-
8
[Correspondence] How to find panellists for a global health conference
-
9
[Correspondence] Structural silencing and the elephant in the room in global health
-
10
[Correspondence] Global health and its crises: laugh, but then what?
The Lancet Haematology
-
1
[Personal View] Redefining plasma cell leukaemia
-
2
[Review] High time for risk-adapted treatment in mantle cell lymphoma
-
3
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia – Authors' reply
-
4
[Correspondence] Response-adapted inotuzumab ozogamicin in paediatric first-relapse B-cell acute lymphoblastic leukaemia
-
5
[Articles] Topical ruxolitinib for chronic cutaneous graft-versus-host disease: a single-centre, randomised, double-blind, intra-patient-controlled phase 2 trial
-
6
[Articles] Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
-
7
[Editorial] Personalising AML treatment: beyond age and fitness
-
8
[In Focus] From approval to practice: are clinicians and health systems ready for gene therapy in sickle cell disease?
-
9
[In Focus] Vernon Louw: expanding access to clinical haematology in Africa
-
10
[Articles] Rilzabrutinib, an oral Bruton tyrosine kinase inhibitor, in patients with warm autoimmune haemolytic anaemia: a prospective, single-arm, multicentre, phase 2b safety and clinical activity study (LUMINA 2)
The Lancet Healthy Longevity
-
1
[Editorial] Making dementia clinical trials more representative
-
2
[Articles] Social connection and intrinsic capacity in later life across the USA, England, Europe, China, and Japan: a harmonised multicohort longitudinal study
-
3
[Comment] Hearing loss, hearing aids, and longevity: from association to intervention
-
4
[Articles] Hearing loss, hearing-aid use, and mortality risk: individual participant data meta-analysis of population-based studies from Australia, Iceland, and the USA and a replication study from Norway
-
5
[Comment] Healthy ageing for all? Socioeconomic inequalities in intrinsic capacity across generations
-
6
[Articles] Cohort trends in intrinsic capacity in Europe: a population-based longitudinal study
-
7
[Articles] RSV prefusion F vaccine effectiveness in older adults with immunosuppression: a prespecified analysis of the DAN-RSV trial
-
8
[Articles] Effect of pre-existing dementia on cancer-specific and all-cause mortality in patients with cancer in Denmark: a population-based cohort study
-
9
[Personal View] Sarcopenia as a manifestation of systemic energetic failure with ageing
-
10
[Feature] Highlights of AAIC 2026
The Lancet HIV
-
1
[Corrections] Correction to Lancet HIV 2026; 13: e478–89
-
2
[Comment] Ebola virus disease outbreaks and HIV control
-
3
[Corrections] Correction to Lancet HIV 2026; 13: e440–51
-
4
[Corrections] Correction to Lancet HIV 2026; 13: e569–610
-
5
[Corrections] Correction to Lancet HIV 2026; 13: e557–68
-
6
[Editorial] Turkish Government crackdown on HIV and LGBTQ+ groups
-
7
[Review] Metabolic dysfunction-associated steatotic liver disease in people living with HIV: a framework for integrated screening and care
-
8
[Comment] Advancing a fixed-dose combination for children with HIV
-
9
[Articles] Expediting a UNIVERSAL first-line regimen of a dolutegravir–emtricitabine–tenofovir alafenamide fixed-dose ratio for children living with HIV older than 4 weeks: a 24-week, open-label, single-arm, phase 1–2, pharmacokinetic, safety, and antivir
-
10
[Articles] Plasma dolutegravir exposure testing to identify people with HIV at highest risk for dolutegravir resistance (ITREMA-2): a two-centre, prospective implementation study in South Africa
The Lancet Infectious Diseases
-
1
[Newsdesk] Increase of West Nile virus cases in Europe
-
2
[Newsdesk] African countries' effort to interrupt polio outbreaks
-
3
[Newsdesk] The 17th annual NTD NGO Network conference
-
4
[Newsdesk] Momentum builds for the global elimination of trachoma
-
5
[Obituary] Vasee Moorthy
-
6
[Newsdesk] Research in brief
-
7
[Profile] Dora Buonfrate—making strongyloidiasis less neglected
-
8
[Editorial] Hope for efficacious vaccines for Bundibugyo virus
-
9
[Clinical Picture] Mucocutaneous leishmaniasis caused by Leishmania infantum in a Norwegian patient receiving TNF-α inhibitor therapy
-
10
[Corrections] Correction to Lancet Infectious Dis; published online Aug 25 https://doi.org/10.1016/S1473-3099(26)00318-X
The Lancet Microbe
-
1
[Editorial] AMR stewardship needs microbiology
-
2
[Comment] Advancing Group A Streptococcus vaccines: barriers, models, and the path to rheumatic fever prevention
-
3
[Series] Mechanisms underlying rheumatic heart disease immune-mediated pathogenesis: T-cell responses, cytokine networks, and immune dysregulation as drivers of valvular injury
-
4
[Articles] Burden and genomic characterisation of Shigella-associated diarrhoea in children younger than 5 years in Lusaka, Zambia: a prospective cohort study
-
5
[Articles] Antibody dynamics after melioidosis infection in Thailand: a retrospective cohort study
-
6
[Articles] Effects of attenuated influenza virus administration to young children on pneumococcal density and acquisition in UK families: a randomised controlled trial
-
7
[Review] From microbiomes to predictive ecosystems: challenges and opportunities in artificial intelligence-based approaches
-
8
[News] Rare Ebola species drives new outbreak
-
9
[Personal View] Learning from inconsistencies: refining biomarker discovery in viral diseases
-
10
[Correspondence] Optimising tongue-swab Xpert MTB/RIF Ultra testing as a diagnostic system
The Lancet Neurology
-
1
[Articles] Plasma phosphorylated tau 217 concentrations, APOE genotype, and timing of cognitive impairment in individuals across diverse racial and ethnic groups: a pooled analysis of prospective cohort studies
-
2
[Comment] The use of blood biomarkers to understand responses to lecanemab treatment
-
3
[Articles] Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study
-
4
[Policy View] Reframing traumatic brain injury and spinal cord injury as chronic multisystem disorders: toward integrated, long-term care
-
5
[Editorial] Neurotrauma as a chronic disease: a call for integrated care
-
6
[In Context] A Ferrier sesquicentenary
-
7
[Articles] Safety and efficacy of delpacibart zotadirsen in Duchenne muscular dystrophy mutations amenable to exon 44 skipping in the USA (EXPLORE44): a randomised, placebo-controlled, double-blind, phase 1/2 trial
-
8
[Comment] From syndrome to antibody-defined autoimmune encephalitides
-
9
[Correspondence] Staged bilateral focused ultrasound pallidothalamic tractotomy for Parkinson's disease
-
10
[Correspondence] Staged bilateral focused ultrasound pallidothalamic tractotomy for Parkinson's disease
The Lancet Oncology
-
1
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC
-
2
[Corrections] Correction to Lancet Oncol 2026; 27: 1077–93
-
3
[Perspectives] Differing approaches to cancer at the Edinburgh Fringe
-
4
[Articles] Global burden of cancer attributable to infections in 2024: a worldwide incidence analysis
-
5
[Review] Cancer and the microbiome: from association to intervention
-
6
[Comment] England's National Cancer Plan; ambition without accountability
-
7
[Comment] Blank spaces on the map: genomics for global cancer research
-
8
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer – Authors' reply
-
9
[Correspondence] Re-evaluating aglatimagene in localised prostate cancer
-
10
[Correspondence] Proton pump inhibitors and durvalumab in PACIFIC
The Lancet Planetary Health
-
1
[Articles] Premature mortality and economic losses attributable to landscape fire-related PM2·5 in ten countries and territories: a causal analysis
-
2
[Review] Climate change and animal infectious diseases: a systematic review of emerging evidence
-
3
[Editorial] Future proofing food systems
-
4
[Comment] Urban green spaces: balancing benefits with risks from vector-borne diseases, pesticide exposure, and allergies
-
5
[Articles] Oil and gas well development and coccidioidomycosis risk in Kern County, CA, USA: a case-crossover study
-
6
[Articles] Exploring China’s Clean Air Act and associated cardiovascular disease risk: a prospective, quasi-experimental, and causal inference modelling study
-
7
[Articles] Direct and spillover hospitalisation patterns during climate hazards across regions of different health-system resilience levels in China: a nationwide retrospective analysis
-
8
[Viewpoint] From population to individual: advocating personalised digital tools for heat-health early warning in a changing climate
-
9
[Articles] Impacts of climate-driven yield changes on the affordability of healthy diets: a modelling study
-
10
[Newsdesk] Planetary Health Research Digest